ERAS
ERAS clinical trials: Erasca, Inc.
Every trial on ClinicalTrials.gov where Erasca, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 9
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ERAS on the catalyst calendar · ERAS registry changes
- Primary completion May 1, 2028Sponsor estimatePhase 1NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsErasca, Inc. · Metastatic Solid TumorsRecruitingERASLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2026ActualPhase 1/Phase 2NCT04866134A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsErasca, Inc. · Advanced or Metastatic Solid TumorsCompletedERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2026ActualPhase 1NCT04670679A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsErasca, Inc. · Advanced or Metastatic Solid TumorsCompletedERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 15, 2025ActualPhase 1/Phase 2NCT05039177A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesErasca, Inc. · Metastatic Colorectal CancerCompletedERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 3NCT06346067A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Erasca, Inc. · Advanced or Metastatic NRAS-mutant MelanomaActive, not recruitingERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2025ActualPhase 1NCT05907304A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsErasca, Inc. · Advanced or Metastatic Solid TumorsActive, not recruitingERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2028Sponsor estimatePhase 1NCT07021898A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.Erasca, Inc. · Metastatic Solid TumorsRecruitingERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2023ActualPhase 1NCT04959981A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCErasca, Inc. · Advanced Non-squamous Non-small-cell Lung CancerCompletedERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2025Sponsor estimatePhase 1/Phase 2NCT05279859A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesErasca, Inc. · Acute Myeloid LeukemiaWithdrawnERASLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2031Sponsor estimatePhase 1/Phase 2NCT07897734TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC...Tango Therapeutics, Inc. · PDACNot yet recruitingTNGXLeadERASCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2025Sponsor estimatePhase 1NCT05222802A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)Katmai Pharmaceuticals Inc. · Glioblastoma MultiformeActive, not recruitingERASCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner